Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

Final appraisal determination

Final appraisal determination document (PDF 610 KB)

Committee papers (PDF 2.29 MB)

Draft guidance

Appraisal consultation document (PDF 513 KB)

Committee papers (PDF 14.5 MB)

Assessment report (PDF 4.48 MB)

Protocol (PDF 321 KB)

Response to comments on scope and matrix (PDF 256 KB)

Equality impact assessment form (PDF 64 KB)

Final matrix (PDF 102 KB)

Final scope (PDF 105 KB)

Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy): draft scope (post-referral) (PDF 129 KB)

Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy): provisional matrix (post-referral) (PDF 93 KB)